Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy

Blood

Volumn 94, Issue 2, 1999, Pages 673-683

  Massaia, Massimo ^a   Borrione, Paolo ^b   Battaglio, Silvano ^b   Mariani, Sara ^b   Beggiato, Eloise ^b   Napoli, Patrizia ^b   Voena, Claudia ^b   Bianchi, Alberto ^b   Coscia, Marta ^b   Besostri, Barbara ^b   Peola, Silvia ^b   Stiefel, Thomas ^b   Even, Jos ^b   Novero, Domenico ^b   Boccadoro, Mario ^b   Pileri, Alessandro ^b  

^a Dipto di Med e Oncol Sperimentale Div Universitaria di Ematologia   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; VACCINATION;

EID: 0033566327     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.673.414k30_673_683     Document Type: Article

References (56)

1. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 330:484, 1994
2. Boccadoro M, Pileri A: Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 11:111, 1997
3. Gianni AM, Tarella C, Bregni M, Siena S, Lombardi F, Gandola L, Caracciolo D, Stern A, Bonadonna G, Boccadoro M, Pileri A: High dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 12:503, 1994
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91, 1996
5. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B: Autotransplants in multiple myeloma: What have we learned? Blood 88:838, 1996
6. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A: High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596, 1995
7. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto F, Vegna ML, Dammacco F, Pileri A: Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. N Engl J Med 322:1430, 1990
8. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 12:2405, 1994
9. Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W: Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 16:890, 1998
10. Dianzani U, Pileri A, Boccadoro M, Palumbo A, Pioppo P, Blanchi A, Camponi A, Battaglio S, Massaia M: Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status. Blood 72:1064, 1988
11. 2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother 34:157, 1991
12. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86:3043, 1995
13. Yi Q, Eriksson I, He W, Holm G, Mellstedt H, Osterborg A: Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4+ and CD8+ subsets. Br J Haematol 96:338, 1997
14. Yi Q, Holm G, Lefvert AK: Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin Exp Immunol 104:359, 1996
15. Massaia M, Bianchi A, Attisano C, Peola S, Redoglia V, Dianzani U, Pileri A: Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 78:1770, 1991
16. Massaia M, Attisano C, Peola S, Carlesso N, Omedè P, Ferrero D, Corradini P, Boccadoro M, Bianchi A, Pileri A: Rapid generation of effective anti-tumor T cells in the bone marrow of myeloma patients by CD3 engagement. Blood 82:1787, 1993
17. Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, Bianchi A, Boccadoro M, Pileri A: Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85:3679, 1995
18. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN: Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540, 1972
19. Hannestad K, Kao MS, Eisen HN: Cell-bound myeloma proteins on the surface of myeloma cells: Potential targets for the immune system. Proc Natl Acad Sci 69:2295, 1972
20. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
21. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129, 1997
22. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996
23. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711, 1996
24. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206, 1997
25. + donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671, 1998
26. Durie BGM, Salmon SE: Multiple myeloma, macroglobulinemia and monoclonal gammopathies, in Hoffbrand AV, Brown MC, Hirsh J (eds): Recent Advances in Haematology. Edinburgh, UK, Churchill Livingstone, 1977, p 243
27. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting features, response to treatment, and survival. Cancer 36:842, 1975
28. Palumbo A, Pileri A, Triolo S, Omede P, Bruno B, Ciravegna G, Galliano M, Frieri R, Boccadoro M: Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 19:23, 1997
29. Battaglio S, Napoli P, Beggiato E, Borrione P, Ciaiolo C, Peola S, Bianchi A, Stiefel T, Boccadoro M, Pileri A, Massaia M: Development of vaccines against autologous tumor-derived idiotype in human myeloma: Rationale and preparation. Minerva Biotec 8:1, 1996
30. Corradini P, Boccadoro M, Voena C, Pileri A: Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin IgG- and IgA-secreting multiple myelomas. J Exp Med 178:1091, 1993
31. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, Pileri A, Corradini P: A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11:1793, 1997
32. Valerio RM, Bray AM, Campbell RA, DiPasquale A, Margellis C, Rodda SJ, Geysen HM, Maeji NJ: Multipin peptide synthesis at the micromole scale using 2-hydroxyethyl methacrylate grafted polyethylene supports. Int J Pept Protein Res 42:1, 1993
33. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294, 1979
34. Scwab R, Szabo P, Manavalan JS, Weksler ME, Posnett DN, Pannetier C, Kourilsky P, Even J: Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 158:4493, 1997
35. Genevée C, Diu A, Nierat J, Caignard A, Dietrich PY, Ferradini L, Roman RS, Triebel F, Hercend T: An experimentally validated panel of subfamily-specific oligoucleotide primers (Valpha1-w29/Vbeta1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol 22:1261, 1992
36. Wei S, Charmley P, Robinson MA, Concannon P: The extent of the human germline T-cell receptor V beta segment repertoire. Immunogenetics 40:27, 1994
37. Pusieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P: Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 153:2807, 1994
38. Pannetier C, Even J, Kourilsky P: T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 16:176, 1995
39. Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D: Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13:2354, 1995
40. Ludwig H, Cohen AM, Polliack A, Huber H, Nachbaur D, Senn HJ, Morant R, Eckhardt S, Gunczler P, Seewann HL: Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of others' studies. Ann Oncol 6:467, 1995
41. Abrahamson GM, Bird JM, Newland AC, Gaminara E, Giles C, Joyner M, Kelsey SM, Lewis D, McCarthy DM, Roques AW, Tew CJ, Treacy M, van de Pette J, Samson D: A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 94:659, 1996
42. Peest D, Deicher H, Coldewey R, Leo R, Bart1 R, Bartels H, Braun HJ, Fett W, Fischer JT, Gobel B: A comparison of polychemotherapy and melphalan/prednisone for primary remission induction and interferon-alpha for maintenance treatment in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 89:328, 1995
43. Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92:840, 1996
44. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91:2459, 1998
45. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
46. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328, 1998
47. Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359, 1997
48. Kuramoto Y, Sekita Y, Tagami H: Histoanalytical study of the cellular infiltrate in the tubercolin reaction. Clin Exp Dermatol 18:111, 1993
49. Wen YJ, Lim SH: T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol 27:1043, 1997
50. Wen YJ, Lim SH: Immunogenicity and cross-reactivity with idiotypic IgA of VHCDR3 peptide in multiple myeloma. Br J Haematol 100:464, 1998
51. Wen YJ, Lim SH: In-vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma. Br J Haematol 103:663, 1998
52. Currier JR, Deulofeut H, Barron KS, Kehn PJ, Robinson MA: Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity. Hum Immunol 48:39, 1996
53. Naumov YN, Hogan KT, Naumova EN, Pagel JT, Gorski J: A class I MHC-restricted recall response to a viral peptide is highly polyclonal despite stringent CDR3 selection: Implications for establishing memory T cell repertoires in "real-world" conditions. J Immunol 160:2842, 1998
54. Deulofeut H, Robinson MA: The human T cell receptor repertoire utilized in response to HbsAg. Hum Immunol 57:54, 1997
55. Farace F, Angevin E, Poullion I, Leboullaire C, Ferir G, Elias D, Escudier B, Triebel F: T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines. Int J Cancer 71:972, 1997
56. Reichardt VL, Okada CY, Liso A, Benike CJ, Stocker-Goldstein KE, Engleman EG, Blume KG, Levy R: Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-A feasbility study. Blood 93:2411, 1999